Skip to content
ChickenStockChickenStock
Research128940
Hanmi Pharmaceutical logo

Hanmi Pharmaceutical (128940) stock

KOSPI · Pharmaceuticals

KRW 459,000-1.40%(-6,500)

As of Nov 16, 11:42 AM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

31.12x

P/B

4.53x

P/S

3.52x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 467.2 billionKRW 131.1 billionKRW 84.1 billion+29.3%
Q1 2026Consolidated · Filed May 15, 2026KRW 392.9 billionKRW 53.6 billionKRW 51.1 billion+0.5%
Q4 2025Consolidated · Filed Mar 20, 2026KRW 433 billionKRW 83.3 billionKRW 54.1 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 362.3 billionKRW 55.1 billionKRW 45.4 billion+0.1%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 361.3 billionKRW 60.4 billionKRW 43 billion-4.5%
Q1 2025Consolidated · Filed May 15, 2025KRW 390.9 billionKRW 59 billionKRW 44.7 billion-3.2%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 20, 2026KRW 1.5 trillionKRW 257.8 billionKRW 187.1 billion—
FY2024Consolidated · Filed Mar 18, 2025KRW 1.5 trillionKRW 216.2 billionKRW 140.4 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
6.45%
Of trading value on Nov 13, 2026
Short-sale value
KRW 6.16 billion
Previous 20-day average 9.49%
Net short position
251,281 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
776,551 shares
As of Nov 13, 2026 · 6.06% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20266.45%KRW 6.16 billion
Nov 12, 20266.85%KRW 12.01 billion
Nov 11, 20265.93%KRW 7.11 billion
Nov 10, 202610.05%KRW 8.28 billion
Nov 9, 202611.47%KRW 10.21 billion
Nov 6, 202613.60%KRW 27.76 billion
Nov 5, 202610.69%KRW 18.67 billion
Nov 4, 20269.04%KRW 4.99 billion
Nov 3, 202613.16%KRW 6.53 billion
Nov 2, 202613.43%KRW 10.12 billion

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Hanmi Pharmaceutical (128940) stock information

KOSPI

Hanmi Pharmaceutical (128940) is listed on KOSPI. Its market capitalization is about KRW 5.9 trillion. On trailing-twelve-month earnings the P/E ratio is 31.12, and the P/B ratio is 4.53. Return on equity is 14.6%. These figures are computed in-house from official filings and are reference information only.

Hanmi Pharmaceutical — frequently asked questions

What is the P/E ratio of Hanmi Pharmaceutical (128940)?
On a trailing-twelve-month basis, 128940 trades at a P/E ratio of 31.12. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Hanmi Pharmaceutical?
128940 has a market capitalization of about KRW 5.9 trillion. The figure moves with the share price and is refreshed each trading day.
Does Hanmi Pharmaceutical pay a dividend?
128940 has a dividend yield of about 0.44%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.